Table 3.

ORs for specific tumor subtypes, stratified by major invasive histologic type, ER/PR status, and hormone therapy type/regimen, among current versus never users of hormone therapy

A.
Ductal: ER+ and/or PR+
Monoestrogen
Cyclical estrogen-progestagen*
Continuous estrogen-progestagen
n/nOR (95% CI)n/nOR (95% CI)n/nOR (95% CI)
Grade
139/882.10 (1.41-3.14)33/882.17 (1.41-3.34)111/883.60 (2.65-4.90)
261/3420.87 (0.65-1.17)80/3421.47 (1.12-1.93)198/3421.80 (1.47-2.20)
3+26/1800.73 (0.47-1.12)34/1801.23 (0.84-1.82)59/1801.03 (0.75-1.42)
Size
TI81/2901.25 (0.96-1.64)99/2901.94 (1.50-2.51)243/2902.32 (1.90-2.83)
T240/2410.90 (0.63-1.28)36/2411.02 (0.70-1.49)117/2411.67 (0.30-2.13)
T3+4/560.41 (0.15-1.16)7/560.93 (0.41-2.10)4/560.26 (0.09-0.74)
Nodes
081/3281.14 (0.87-1.48)100/3281.79 (1.39-2.32)258/3282.25 (1.86-2.72)
1+40/2430.89 (0.62-1.27)35/2430.98 (0.67-1.43)97/2431.34 (1.04-1.74)
Her2/neu
Negative100/4331.12 (0.88-1.43)110/4331.55 (1.22-1.98)269/4331.91 (1.60-2.29)
Positive15/1260.59 (0.34-1.02)28/1261.33 (0.90-2.14)60/1261.38 (0.99-1.94)
B.
Ductal: ER− and PR−
Monoestrogen
Cyclical estrogen-progestagen
Continuous estrogen-progestagen

n/n
OR (95% CI)
n/n
OR (95% CI)
n/n
OR (95% CI)
Grade
10/43/44.38 (0.92-20.88)2/41.38 (0.24-8.02)
29/470.80 (0.37-1.73)8/471.05 (0.49-2.27)17/471.06 (0.59-1.92)
3+26/1370.97 (0.63-1.50)16/1370.76 (0.45-1.30)53/1371.24 (0.88-1.75)
Size
TI18/740.99 (0.57-1.71)11/740.82 (0.43-1.56)34/741.22 (0.79-1.88)
T211/850.70 (0.37-1.33)15/851.21 (0.69-2.14)35/851.39 (0.91-2.12)
T3+3/171.11 (0.31-3.94)1/170.48 (0.06-3.69)2/170.48 (0.11-2.15)
Nodes
024/1051.07 (0.67-1.69)17/1050.97 (0.57-1.66)43/1051.16 (0.79-1.71)
1+7/690.47 (0.20-1.08)10/690.95 (0.48-1.89)26/691.27 (0.79-2.05)
Her2/neu
Negative17/1120.71 (0.42-1.23)21/1121.13 (0.70-1.85)40/1121.04 (0.70-1.53)
Positive14/611.13 (0.62-2.07)3/610.33 (0.10-1.05)26/611.44 (0.88-2.34)
C.
Lobular/tubular/mixed ductal-lobular: ER+ and/or PR+
Monoestrogen
Cyclical estrogen-progestagen
Continuous estrogen-progestagen

n/n
OR (95% CI)
n/n
OR (95% CI)
n/n
OR (95% CI)
Grade
120/402.19 (1.25-3.84)25/403.68 (2.17-6.24)54/403.88 (2.50-6.01)
254/1311.93 (1.37-2.72)55/1312.83 (2.00-3.99)164/1314.18 (3.23-5.41)
3+7/301.30 (0.56-3.03)11/302.64 (1.28-5.44)15/301.72 (0.90-3.31)
Size
TI47/932.22 (1.52-3.22)52/933.39 (2.35-4.91)151/934.88 (3.67-6.49)
T228/821.53 (0.97-2.41)34/822.64 (1.72-4.04)66/822.50 (1.76-3.55)
T3+5/201.92 (0.69-5.30)5/202.68 (0.96-7.44)13/203.38 (1.59-7.17)
Nodes
057/1142.32 (1.64-3.26)61/1143.43 (2.44-4.83)165/1144.57 (3.49-5.97)
1+21/741.32 (0.79-2.21)25/742.22 (1.38-3.58)58/742.53 (1.75-3.66)
Her2/neu
Negative68/1472.10 (1.54-2.87)77/1473.32 (2.45-4.52)191/1474.12 (3.23-5.24)
Positive7/390.95 (0.42-2.17)5/390.87 (0.34-2.26)27/392.32 (1.37-3.94)
  • NOTE: All three tables shown include parts of the same statistical model for respective tumor characteristics (grade, size, nodes). Although also part of these models, lobular/tubular/mixed ER− and PR− subtype data are not presented here, due to very small numbers after stratification by hormone therapy type and regimen.

  • * Estrogen-progestagen: combined estrogen-progestagen menopausal hormone therapy.

  • n, current hormone therapy users/never hormone therapy users (with corresponding numbers for controls being monoestrogen, 546/2,685; cyclical estrogen-progestagen, 422/2,685; and continuous estrogen-progestagen, 853/2,685).

  • ORs adjusted for same potential confounders as in Table 2.